Exercise therapy vs no treatment four to six weeks after lumbar disc surgery
Functional status, long‐term · patients four to six weeks after lumbar disc surgery
1 finding from 1 review
- no estimate extracted226 participantsLow
Findings
What do systematic reviews say?
2,640 questions · 2,709 findings · 446 reviews
No studies found 593 · 21.9%GRADE not reported 241 · 8.9%Very low 538 · 19.9%Low 706 · 26.1%Moderate 516 · 19%High 115 · 4.2%
High‐intensity exercise vs low‐intensity exercise programmes four to six weeks after lumbar disc surgery
Functional ability · patients four to six weeks after lumbar disc surgery
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Supervised programmes vs home exercises
Functional ability · patients four to six weeks after lumbar disc surgery
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Inhaled NO vs placebo or conventional therapy
Long‐term mortality · all infants and children with congenital heart disease having postoperative management of pulmonary hypertension
1 finding from 1 review
- Inhaled nitric oxide for the postoperative management of pulmonary hypertension in infants and children with… 2014 · Cochrane Headline outcomes onlyno estimate extracted0 studies · 0 participantsGRADE not reported
Computer‐assisted reconstruction surgery vs conventional operating techniques
IKDC knee examination grade normal (grade A) or nearly normal (grade B) ‐ Intermediate/long‐term · People, primarily adults, undergoing ACL reconstruction surgery
Computer‐assisted reconstruction surgery showed no clear difference in IKDC knee examination grade normal (grade A) or nearly normal (grade… compared with conventional operating techniques (low certainty).
1 finding from 1 review
- RR 1.01 [0.96, 1.06]3 studies · 173 participantsLow
SULPIRIDE vs placebo
Global state: clinically significant response in global state ‐ by long term ‐ not measured · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
SULPIRIDE vs placebo
Quality of life: average score ‐ by long term ‐ not measured · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Intervention not reported
Long‐term complications (one year or more after surgery) · people with age‐related cataract
The review found no eligible studies for this question.
1 finding from 1 review
- Manual small incision cataract surgery (MSICS) with posterior chamber intraocular lens versus extracapsular cataract… 2014 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Thyrotropin‐releasing hormone tartrate vs placebo
Longer‐term (minimum 1 month) change in generic quality of life scores · people with speech disorder resulting from hereditary ataxias
1 finding from 1 review
- Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes 2014 · Cochrane Headline outcomes onlyno estimate extracted0 studies · 0 participantsGRADE not reported
Thyrotropin‐releasing hormone tartrate vs placebo
Longer‐term burdens (minimum 1 month) (for example, demands on caregivers, frequency of tests, restrictions on lifestyle) · people with speech disorder resulting from hereditary ataxias
1 finding from 1 review
- Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes 2014 · Cochrane Headline outcomes onlyno estimate extracted0 studies · 0 participantsGRADE not reported
Varenicline vs placebo
Generic quality of life measures · people with speech disorder resulting from hereditary ataxias
1 finding from 1 review
- Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes 2014 · Cochrane Headline outcomes onlyno estimate extracted1 study · 13 participantsVery low
Varenicline vs placebo
Longer‐term burdens (minimum 1 month) (for example, demands on caregivers, frequency of tests, restrictions on lifestyle) · people with speech disorder resulting from hereditary ataxias
1 finding from 1 review
- Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes 2014 · Cochrane Headline outcomes onlyno estimate extracted0 studies · 0 participantsGRADE not reported
Riluzole vs placebo
Longer‐term (minimum 1 month) change in generic quality of life scores · people with speech disorder resulting from hereditary ataxias
1 finding from 1 review
- Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes 2014 · Cochrane Headline outcomes onlyno estimate extracted0 studies · 0 participantsGRADE not reported
Riluzole vs placebo
Longer‐term burdens (minimum 1 month) (for example, demands on caregivers, frequency of tests, restrictions on lifestyle) · people with speech disorder resulting from hereditary ataxias
1 finding from 1 review
- Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes 2014 · Cochrane Headline outcomes onlyno estimate extracted0 studies · 0 participantsGRADE not reported
Idebenone vs placebo
Longer‐term (minimum 1 month) change in generic quality of life scores · people with speech disorder resulting from hereditary ataxias
1 finding from 1 review
- Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes 2014 · Cochrane Headline outcomes onlyno estimate extracted0 studies · 0 participantsGRADE not reported
Idebenone vs placebo
Longer‐term burdens (minimum 1 month) (for example, demands on caregivers, frequency of tests, restrictions on lifestyle) · people with speech disorder resulting from hereditary ataxias
1 finding from 1 review
- Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes 2014 · Cochrane Headline outcomes onlyno estimate extracted0 studies · 0 participantsGRADE not reported
Physiotherapy and occupational therapy vs placebo
Longer‐term (minimum 1 month) change in generic quality of life scores · people with speech disorder resulting from hereditary ataxias
1 finding from 1 review
- Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes 2014 · Cochrane Headline outcomes onlyno estimate extracted0 studies · 0 participantsGRADE not reported
Hydroxytryptophan vs placebo
Longer‐term (minimum 1 month) change in generic quality of life scores · people with speech disorder resulting from hereditary ataxias
1 finding from 1 review
- Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes 2014 · Cochrane Headline outcomes onlyno estimate extracted0 studies · 0 participantsGRADE not reported
Physiotherapy and occupational therapy vs placebo
Longer‐term burdens (minimum 1 month) (for example, demands on caregivers, frequency of tests, restrictions on lifestyle) · people with speech disorder resulting from hereditary ataxias
1 finding from 1 review
- Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes 2014 · Cochrane Headline outcomes onlyno estimate extracted0 studies · 0 participantsGRADE not reported
Betamethasone vs placebo
Generic quality of life measures · people with speech disorder resulting from hereditary ataxias
1 finding from 1 review
- Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes 2014 · Cochrane Headline outcomes onlyno estimate extracted0 studies · 0 participantsGRADE not reported